BSECompany Update7 Oct 2026 · 7 Oct 2026, 02:35 pm

In continuation of the Company''s letters dated 05/Sep/2026 and 15/Sep/2026, this is to inform you that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA stands terminated. The proposal to acquire 1.50% each of the equity shares of common stock of Med Therapy by Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company also stands terminated.

Sudarshan Pharma Industries Ltd · 543828

✦ AI SummaryOrder Cancel

Sudarshan Pharma Industries Ltd has terminated its proposal to acquire 9.50% equity shares of Med Therapy Biotechnology Inc. and also terminated the proposal to acquire 1.50% each of the equity shares by its promoters, Mr. Hemal Mehta and Mr. Sachin Mehta.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

Attachments (1)

📄

c46a44c9-fffa-49f9-9742-b8dcc63296ab.pdf

pdf

Download →
View document text
SUDARTHAX PHARIIA IIIDUOTRIES TTD Head Office : 301 . Au ra Biplex Premum Beta I Premises, 7, S.V Boad, Borival (West), ft,lumba 400092 E-mail : compl ance@)sudarshanpharma.com Websile : www.sltdarshanpharma com BoardLine : +91'22-42221111 i 13331111 i 42221116 (100 ljne) . CIN : 151 496[,1H2008P LC 1 84997 Date:7t'October 2026 sPL/CSISE/2026 27 /61 Th€ Listing Department BSE Limited BSE Scrip Code:543828 Phlroze leeieebhoY Towers, BSE Trading Symbol: SUDARSHAN Dalal Street, Murnbai 400 001 lS N: NEOOTVO1023 Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obli8ations and Disclosure Requirements) Regulations, 2015 Ref: Updates on acquisition of M/s. MedTherapy giotechnology lnc, UsA-Company Letter bearing daftd ref. no. spfL/cs/sE/2026-2027l57 dated 5th september, 2026 and sPlLlcslsEl2o26'2o2715a 15th september,2026 Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations' 2015 and n contlnUat]on of the Company,s lette15 bearing ref' no, s P lL/cs/s E/2 026.2021 157 daled 5 ' september, 2026 an d sPll/cslsE/2o26'2a27/58 clated 1sth september, 2026, this ls to inform vou that the proposal to acqulre 9 50% equitY share! of common stock of Med Therapy Biotechnology lnc ' USA {"Med Therapy") stands terminated The proposa to acqlire 150% each of the equity shares of common stock of Med TherapY' bY N4r.HemalMehta(Chalrman&ManagngDirector)andMr'sachinMehta(JointManaglngDirector)' Promoters of the Company also stands termlnated. You are requested to take the same on record For, Sudarshan Pharma lndustries Limited lndll HemalMehta Chalrman & Managlng Director Begd. Otl. : 301, Aura Biplex, Above Kalyan Jewellers, S.V Road, Borivali (West), lvumbai - 400092